Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Drug Makers Can Now Access MID-NET from Their Own Offices
July 11, 2022
- Japan to Discuss Fourth COVID Shot for Below Age 60: Govt Official
July 8, 2022
- Panel Designates COVID, Monkeypox and Other Priority Infectious Diseases for SCARDA Funding
July 8, 2022
- All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
- MHLW Preparing Inspection Manual after GMP Issues, Draft Due Out by March-End
July 5, 2022
- 8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem
July 4, 2022
- 5 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 4, 2022
- Online NDA Submission Starts in Japan: MHLW/PMDA
July 4, 2022
- VLP and Shionogi 1st to Be Selected for SCARDA Vaccine Funding Program
July 4, 2022
- FDA Philippines to Expedite Review Process of Japan-Approved Drugs
July 1, 2022
- AMED Employees’ Annual Pay Averaged 9.3 Million Yen in FY2021
July 1, 2022
- Ryukaikon to Assess Situation of Products Distributed by Single Wholesalers
July 1, 2022
- MHLW Panel to Discuss Cultivation of Cannabis for Use as Pharmaceutical Ingredient
July 1, 2022
- Survey Finds 11.7% of Wholesaler Transactions Negotiated through Proxies: MHLW
June 30, 2022
- Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
- Average Annual Pay for PMDA Staffers at 7.7 Million Yen in FY2021
June 29, 2022
- MHLW Drafts Guidelines on Development of Recombinant Viral Vaccines
June 29, 2022
- Safety of Emergency Approval Products to Be Monitored with RMP: Official
June 27, 2022
- MHLW Panel OKs 56 More Health Damage Claims for COVID-19 Vaccines
June 27, 2022
- Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
June 27, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…